Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

November 27, 2018

Primary Completion Date

August 1, 2025

Study Completion Date

August 1, 2025

Conditions
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or LymphomaDose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
Interventions
BIOLOGICAL

mRNA-2752

Solution for intratumoral injection

BIOLOGICAL

Durvalumab

Solution for infusion after dilution

Trial Locations (24)

2145

Westmead Hospital, Westmead

3004

Alfred Health, Melbourne

6009

One Clinical Research Perth, Nedlands

10016

NYU Langone Medical Center, New York

10029

Icahn School of Medicine at Mount Sinai, New York

14642

James P. Wilmot Cancer Center, Rochester

34232

Sarah Cannon Research Institute at Florida Cancer Specialists, Sarasota

37203

Sarah Cannon Research Institute, Nashville

44195

The Cleveland Clinic Foundation, Cleveland

48202

Henry Ford Hospital, Detroit

60637

The University of Chicago Medicine, Chicago

80045

University of Colorado Denver, Aurora

90404

Providence St. John's Health Center, Santa Monica

94143

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

3109601

Rambam Medical Center, Haifa

4941492

Rabin Medical Center, Petah Tikva

5224213

Chaim Sheba Medical Center, Ramat Gan

6423906

Tel Aviv Sourasky Medical Center, Tel Aviv

06510

Yale Cancer Center, New Haven

02114

Massachusetts General Hospital, Boston

02215

Cancer Center at Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

97239-3011

Oregon Health and Science University, Portland

Unknown

Melanoma Institute of Australia, Wollstonecraft

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

ModernaTX, Inc.

INDUSTRY